SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Antonio Calles, Nicholas Kwiatkowski, Bernard K. Cammarata, Dalia Ercan, Nathanael S. Gray, Pasi A. Jänne, Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines, Molecular Oncology, 2015, 9, 1, 260

    CrossRef

  2. 2
    S. Pant, M. Saleh, J. Bendell, J. R. Infante, S. Jones, C. D. Kurkjian, K. M. Moore, J. Kazakin, G. Abbadessa, Y. Wang, Y. Chen, B. Schwartz, L. H. Camacho, A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors, Annals of Oncology, 2014, 25, 7, 1416

    CrossRef

  3. 3
    Nicolas Girard, Clarisse Audigier-Valette, Alexis B Cortot, Bertrand Mennecier, Didier Debieuvre, David Planchard, Gérard Zalcman, Denis Moro-Sibilot, Jacques Cadranel, Fabrice Barlési, ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?, Expert Review of Anticancer Therapy, 2014, 1

    CrossRef

  4. 4
    Laura P. Stabile, Mary E. Rothstein, Christopher T. Gubish, Diana E. Cunningham, Nathan Lee, Jill M. Siegfried, Co-targeting c-Met and COX-2 Leads to Enhanced Inhibition of Lung Tumorigenesis in a Murine Model with Heightened Airway HGF, Journal of Thoracic Oncology, 2014, 9, 9, 1285

    CrossRef

  5. 5
    Morgana D. da Silva, Franciane Bobinski, Karina L. Sato, Sandra J. Kolker, Kathleen A. Sluka, Adair R. S. Santos, IL-10 Cytokine Released from M2 Macrophages Is Crucial for Analgesic and Anti-inflammatory Effects of Acupuncture in a Model of Inflammatory Muscle Pain, Molecular Neurobiology, 2014,

    CrossRef

  6. 6
    Yan Jin, Ping-Li Sun, Hyojin Kim, An Na Seo, Sanghoon Jheon, Choon-Taek Lee, Jin-Haeng Chung, MET Gene Copy Number Gain is an Independent Poor Prognostic Marker in Korean Stage I Lung Adenocarcinomas, Annals of Surgical Oncology, 2014, 21, 2, 621

    CrossRef

  7. 7
    Igor Puzanov, Jeffrey Sosman, Armando Santoro, Muhammad W. Saif, Laura Goff, Grace K. Dy, Paolo Zucali, Julie A. Means-Powell, Wen Wee Ma, Matteo Simonelli, Robert Martell, Feng Chai, Maria Lamar, Ronald E. Savage, Brian Schwartz, Alex A. Adjei, Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors, Investigational New Drugs, 2014,

    CrossRef

  8. 8
    F. Gelsomino, F. Facchinetti, E.R. Haspinger, M.C. Garassino, L. Trusolino, F. De Braud, M. Tiseo, Targeting the MET gene for the treatment of non-small-cell lung cancer, Critical Reviews in Oncology/Hematology, 2014, 89, 2, 284

    CrossRef

  9. 9
    Elena Rota Caremoli, Roberto Labianca, Tivantinib: critical review with a focus on hepatocellular carcinoma, Expert Opinion on Investigational Drugs, 2014, 23, 11, 1563

    CrossRef

  10. 10
    N Yamamoto, H Murakami, H Hayashi, Y Fujisaka, T Hirashima, K Takeda, M Satouchi, K Miyoshi, S Akinaga, T Takahashi, K Nakagawa, CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer, British Journal of Cancer, 2013, 109, 11, 2803

    CrossRef

  11. 11
    F Zagouri, Z Bago-Horvath, F Rössler, A Brandstetter, R Bartsch, C A Papadimitriou, C Dimitrakakis, A Tsigginou, I Papaspyrou, A Giannos, M-A Dimopoulos, M Filipits, High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer, British Journal of Cancer, 2013, 108, 5, 1100

    CrossRef

  12. 12
    Francesca Maria Giugliano, Domingo Alberti, Giovanna Guida, Giampaolo De Palma, Luciano Iadanza, Maria Mormile, Fabrizio Cammarota, Agnese Montanino, Franco Fulciniti, Vincenzo Ravo, Paolo Muto, Non small-cell lung cancer with metastasis to thigh muscle and mandible: two case reports, Journal of Medical Case Reports, 2013, 7, 1, 98

    CrossRef

  13. 13
    Cornel Phillip, Shadia Zaman, Shujun Shentu, Kumudha Balakrishnan, Jiexin Zhang, Veera Baladandayuthapani, Pietro Taverna, Sanjeev Redkar, Michael Wang, Christine Stellrecht, Varsha Gandhi, Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines, Journal of Hematology & Oncology, 2013, 6, 1, 92

    CrossRef

  14. 14
    Giorgio V. Scagliotti, Silvia Novello, Joachim von Pawel, The emerging role of MET/HGF inhibitors in oncology, Cancer Treatment Reviews, 2013, 39, 7, 793

    CrossRef

  15. 15
    Lorenza Rimassa, Nicola Personeni, Matteo Simonelli, Armando Santoro, Tivantinib: a new promising mesenchymal–epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma, Future Oncology, 2013, 9, 2, 153

    CrossRef

  16. 16
    Jing Zhang, Jinsong Liu, Tumor stroma as targets for cancer therapy, Pharmacology & Therapeutics, 2013, 137, 2, 200

    CrossRef

  17. You have free access to this content17
    Grace K. Dy, Alex A. Adjei, Understanding, recognizing, and managing toxicities of targeted anticancer therapies, CA: A Cancer Journal for Clinicians, 2013, 63, 4